Enhertu Approved for HER2-Low Metastatic Breast Cancer
The FDA has approved Enhertu (fam-trastuzumab-deruxtecan-nxki) for adults with unresectable or metastatic HER2-low breast cancer.
Stay updated with breaking news from Accessed August. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The FDA has approved Enhertu (fam-trastuzumab-deruxtecan-nxki) for adults with unresectable or metastatic HER2-low breast cancer.
The FDA has approved Nubeqa (darolutamide) plus docetaxel for the treatment of metastatic hormone-sensitive prostate cancer.
A new citrate-free formulation of Taltz® (ixekizumab) has been made available by Eli Lilly.
FinancialContent fully hosted finance channel
NUBEQA now has indications in both metastatic hormone-sensitive prostate cancer (mHSPC) and non-metastatic castration-resistant prostate cancer (nmCRPC)1Today’s approval under the FDA’s Real-Time Oncology Review (RTOR) pilot program was based on the pivotal Phase III ARASENS trial, which showed a significant overall...